The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
March 7th 2024
The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
CAR T-Cell Therapy Advances in Lymphoma: Implications for Managed Care
1.5 Credits / Hematology, Oncology
View More
Evidence-Based Oncology: Discerning Novel Approaches, Recent Advances, and the Managed Care Considerations for Targeted Treatments in CLL
2.0 Credits / Hematology, Oncology
View More
Leveraging Managed Care to Optimize Patient Outcomes in Acute Myeloid Leukemia
1.5 Credits / Hematology, Oncology
View More
Leveraging Managed Care to Increase Access to BCMA-Directed Treatment and Equitable Care in Multiple Myeloma
1.5 Credits / Hematology, Oncology
View More
New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes
1.5 Credits / Hematology, Oncology
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
AYAs With Hodgkin Lymphoma Face Additional Burdens With Current Clinical Trial Designs
August 8th 2018Advances in Hodgkin lymphoma treatment has led to high survival rates, but adolescents and young adults, who represent the largest age group affected by the disease, face lifelong morbidities from clinical trials. New analytic methods could help inform future protocol changes.
Read More
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16th 2018Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Watch
Riding the Wave Through Chemo: Cancer Journey Leads to chemoWave App for Reporting PROs
June 8th 2018"It is time for patients to have more control over what is prescribed to them and technologies like chemoWave are giving them that power." A cancer diagnosis leads to chemoWave, an app for recording patient-reported outcomes.
Read More
Analyzing Worries in Leukemia and Economic Burden in Lymphoma
June 2nd 2018Two abstracts presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting highlighted patient experiences in blood cancers. One highlighted the worries of patients with acute myeloid leukemia, and the other analyzed economic burdens and resource utilization for patients with non-Hodgkin lymphoma.
Read More
Nelarabine With Chemotherapy Boosted Outcomes in Pediatric and YA Patients With T-Cell Cancers
June 1st 2018A phase 3 study, conducted by the Children’s Oncology Group among children and young adults between ages 1 and 30 diagnosed with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic leukemia, has found a 90% survival rate at 4 years posttreatment initiation—84% of these patients were declared cancer free at that point in their treatment trajectory. Results from this study will be presented at the 2018 American Society of Clinical Oncology Annual Meeting, June 1-5, in Chicago, Illinois.
Read More
Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma
May 31st 2018Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.
Read More
Analysis of patient-reported outcomes found patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were treated with inotuzumab ozogamicin reported better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Read More
Study Reports Highest Survival Rates for Children, Young Adults With Certain T-Cell Leukemias
May 18th 2018A phase III randomized trial, with results being presented in June at the American Society of Clinical Oncology Annual Meeting, found the addition of nelarabine to standard chemotherapy regimen in patients with T-cell malignancies can improve disease-free survival rates.
Read More
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 2nd 2018Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
Read More
Novel Drug Shows Promise in Acute Myeloid Leukemia by Suppressing Two Proteins
April 19th 2018A novel drug that targets MDMX and MDM2, which inhibit a protein that suppresses tumors when they are overexpressed, has tripled the median survival rate in an animal model of human acute myeloid leukemia, according to new research.
Read More
Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma
April 14th 2018Researchers have identified genetic subtypes of diffuse large B-cell lymphoma that revise the molecular classification of the disease and could provide insight into why some patients respond to treatment and others don’t.
Read More
FDA Approves Brentuximab Vedotin for Frontline Treatment of Classical Hodgkin Lymphoma
March 21st 2018The FDA has approved brentuximab vedotin (Adcentris) in combination with chemotherapy for adults with previously untreated state 3 or 4 classical Hodgkin lymphoma based on results of the ECHELON-1 study.
Read More
NCI Researchers Find Drug May Prevent Resistance in Toxin-Based Leukemia Treatment
March 15th 2018A new study recently published in Proceedings of the National Academy of Sciences has identified a possible solution for improving the efficacy of moxetumomab pasudotox, or moxe, in patients with relapsed and chemotherapy-resistant acute lymphoblastic leukemia.
Read More
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
February 28th 2018New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Read More
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
Read More
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Read More
The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"
February 21st 2018Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
Read More
5-Year Survival Rates for Patients With Cancer Worldwide
February 4th 2018CONCORD-3 includes the records of 37.5 million patients diagnosed with cancer from 2000 to 2014, 322 population-based cancer registries in 71 countries and territories, and data on patients' vital status at least 5 years following diagnosis.
Read More
CAR T-Cell Therapy Named ASCO's Advance of the Year
January 31st 2018Chimeric antigen receptor (CAR) T-cell therapy has been named the Advance of the Year in ASCO’s Clinical Cancer Advances 2018. According to the annual report, CAR T-cell therapy is “poised to transform the outlook for children and adults with certain otherwise incurable cancers."
Read More
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 19th 2017The FDA was busy in 2017, with a number of notable approvals, including the first chimeric antigen receptor T-cell treatment. In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, employees from the FDA presented data on 5 new drug approvals in leukemia and lymphoma in 2017.
Read More
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12th 2017Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
Watch
Dr Thomas LeBlanc: Patients With Blood Cancers Less Likely to Use Hospice Care
December 11th 2017Patients with blood cancers tend to use hospice care services less frequently overall than patients with solid tumors. While there has been an increase in hospice care use in patients with blood cancers, there has been a failure to increase hospice use meaningfully, according to Thomas LeBlanc, MD, of the Duke Cancer Institute.
Watch